Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Geisler, Cordelia ^a   Gaisa, Nadine T ^a   Pfister, David ^a   Fuessel, Susanne ^b   Kristiansen, Glen ^c   Braunschweig, Till ^a   Gostek, Sonja ^a   Beine, Birte ^d,e   Diehl, Hanna C ^d   Jackson, Angela M ^f   Borchers, Christoph H ^f,g   Heidenreich, Axel ^a   Meyer, Helmut E ^d,e   Knüchel, Ruth ^a   Henkel, Corinna ^a,d,e  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^f UNIVERSITY OF VICTORIA   (Canada)

^g UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GALECTIN 3; SECERNIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; VINCULIN; NERVE PROTEIN; SCRN1 PROTEIN, HUMAN; VCL PROTEIN, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CARBOHYDRATE METABOLISM; CELL MATURATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION; URINALYSIS; URINE; WESTERN BLOTTING; CHEMISTRY; MOLECULAR DIAGNOSIS; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; TISSUE MICROARRAY;

BIOMARKERS, TUMOR; HUMANS; MALE; MASS SPECTROMETRY; MOLECULAR DIAGNOSTIC TECHNIQUES; NERVE TISSUE PROTEINS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; VINCULIN;

EID: 84947208132     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/454256     Document Type: Article

References (86)

1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics,"CACancer Journal forClinicians, vol. 61, no. 2, pp. 69-90, 2011.
2. I. M. Thompson, M. S. Lucia, and C.M. Tangen, "Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: 'what has been will be again, what has been done will be done again; there is nothing new under the sun'," International Journal of Epidemiology, vol. 36, no. 2, pp. 287-289, 2007.
3. P. J. Bastian, B.H. Carter, A. Bjartell et al., "Insignificant prostate cancer and active surveillance: from definition to clinical implications," European Urology, vol. 55, no. 6, pp. 1321-1332, 2009.
4. E. Klein, "Prostate cancer," Urologic Oncology: Seminars and Original Investigations, vol. 26, no. 5, p. 494, 2008.
5. J. E. McNeal and D. G. Bostwick, "Intraductal dysplasia: a premalignant lesion of the prostate," Human Pathology, vol. 17, no. 1, pp. 64-71, 1986.
6. S. Ashida, H. Nakagawa, T. Katagiri et al., "Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs," Cancer Research, vol. 64, no. 17, pp.5963-5972, 2004.
7. R. Montironi, R. Mazzucchelli, A. Lopez-Beltran, M. Scarpelli, and L. Cheng, "Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance," BJU International, vol. 108, no. 9, pp. 1394-1401, 2011.
8. J.-E. Johansson, O. Andrén, S.-O. Andersson et al., "Natural history of early, localized prostate cancer," The Journal of the American Medical Association, vol. 291, no. 22, pp. 2713-2719, 2004.
9. M. Han, A.W. Partin, S. Piantadosi, J. I. Epstein, and P.C. Walsh, "Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer," The Journal of Urology, vol. 166, no. 2, pp. 416-419, 2001.
10. S. G. Roberts, M. L. Blute, E. J. Bergstralh, J. M. Slezak, and H. Zincke, "PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer," Mayo Clinic Proceedings, vol. 76, no. 6, pp.576-581, 2001.
11. P. H. Lange, C. J. Ercole, D. J. Lightner, E. E. Fraley, and R. Vessella, "The value of serum prostate specific antigen determinations before and after radical prostatectomy," The Journal of Urology, vol. 141, no. 4, pp. 873-879, 1989.
12. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J.D. Pearson, and P. C. Walsh, "Natural history of progression after PSA elevation following radical prostatectomy," Journal of the AmericanMedical Association, vol. 281, no. 17, pp. 1591-1597, 1999.
13. S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher, "Time to detectable metastatic disease in patients with rising prostatespecific antigen values following surgery or radiation therapy," Clinical Cancer Research, vol. 11, no. 24, pp. 8669-8673, 2005.
14. C.-S. Chen, S.-S. Wang, J.-R. Li et al., "PSA density as a better predictor of prostate cancer than percent-free PSA in a repeat biopsy," Journal of the Chinese Medical Association, vol. 74, no.12, pp. 552-555, 2011.
15. C. Y. Hsu, S. Joniau, R. Oyen, T. Roskams, and H. van Poppel, "Detection of clinical unilateral T3a prostate cancer- by digital rectal examination or transrectal ultrasonography?" BJU International, vol. 98, no. 5, pp. 982-985, 2006.
16. T.A. Stamey, M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, and J. Downs, "The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?" Journal of Urology, vol. 172, no. 4, part 1, pp. 1297-1301, 2004.
17. C. H. Bangma, M. J. Roobol, and E. W. Steyerberg, "Predictive models in diagnosing indolent cancer," Cancer, vol. 115, supplement 13, pp. 3100-3106, 2009.
18. G. Guazzoni, M. Lazzeri, L. Nava et al., "Preoperative prostatespecific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer," European Urology, vol. 61, no. 3, pp. 455-466, 2011.
19. A. I. Hinev, V. I. Hadjiev, and N. H. Kolev, "Validation of preoperative nomograms predicting lymph node involvement in prostate cancer: a bi-institutional study," European Urology, vol. 60, no. 6, pp. 1310-1311, 2011.
20. G. L. Andriole, E. D. Crawford, R. L. Grubb III et al., "Mortality results from a randomized prostate-cancer screening trial," The New England Journal ofMedicine, vol. 360, no. 13, pp. 1310-1319, 2009.
21. R. Chou, J. M. Croswell, T. Dana et al., "Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force," Annals of InternalMedicine, vol. 155, no. 11, pp. 762-771, 2011.
22. G. Sandblom, E. Varenhorst, J. Rosell, O. Löfman, and P. Carlsson, "Random is ed prostate cancer screening trial: 20 year follow-up," BritishMedical Journal, vol. 342, no. 7803, Article ID d1539, 2011.
23. F. H. Schroder, J. Hugosson, M. J. Roobol et al., "Screening and prostate-cancermortality in a randomized European study,"The New England Journal ofMedicine, vol. 360, no. 13, pp. 1320-1328, 2009.
24. I. M. Thompson, D. K. Pauler, P. J. Goodman et al., "Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter," The New England Journal of Medicine, vol. 350, no. 22, pp. 2239-2246, 2004.
25. B. H. Gümüs, N. Neşe, M. I. Gündüz, A. R. Kandiloʇlu, Y. Ceylan, and C. Büyüksu, "Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens," International Urology and Nephrology, vol. 36, no. 4, pp. 549-553, 2004.
26. W. W. Hochreiter, "The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis," Andrologia, vol. 40, no. 2, pp. 130-133, 2008.
27. A. Thorpe and D. Neal, "Benign prostatic hyperplasia," The Lancet, vol. 361, no. 9366, pp. 1359-1367, 2003.
28. G. P. Swanson, I. M. Thompson, and J. Basler, "Current status of lymph node-positive prostate cancer: incidence and predictors of outcome," Cancer, vol. 107, no. 3, pp. 439-450, 2006.
29. E. Pin, C. Fredolini, and E. F. Petricoin, "The role of proteomics in prostate cancer research: biomarker discovery and validation," Clinical Biochemistry, vol. 46, no. 6, pp. 524-538, 2013.
30. Z.-D. Han, Y.-Q. Zhang, H.-C. He et al., "Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis," Medical Oncology, vol. 29, no. 4, pp. 2877-2888, 2012.
31. C. Molleken, B. Sitek, C. Henkel et al., "Detection of novel biomarkers of liver cirrhosis by proteomic analysis," Hepatology, vol. 49, no. 4, pp. 1257-1266, 2009.
32. Y. A. Goo and D. R. Goodlett, "Advances in proteomic prostate cancer biomarker discovery," Journal of Proteomics, vol. 73, no.10, pp. 1839-1850, 2010.
33. J. Pang, W.-P. Liu, X.-P. Liu et al., "Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis," Journal of Proteome Research, vol. 9, no. 1, pp. 216-226, 2010.
34. X. Gao, J. Pang, L.-Y. Li et al., "Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer," Oncogene, vol. 29, no.32, pp. 4555-4566, 2010.
35. T. A. Bismar, F. Demichelis, A. Riva et al., "Defining aggressive prostate cancer using a 12-gene model," Neoplasia, vol. 8, no. 1, pp. 59-68, 2006.
36. S. Skvortsov, G. Schäfer, T. Stasyk et al., "Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker," Journal of Proteome Research, vol. 10, no. 1, pp. 259-268, 2011.
37. J. S. Minden, S. R. Dowd, H. E. Meyer, and K. Stühler, "Difference gel electrophoresis," Electrophoresis, vol. 30, supplement 1, pp. S156-S161, 2009.
38. B. Sitek, B. Sipos, G. Klöppel et al., "Application of fluorescence dye saturation labeling for differential proteome analysis of 1, 000 microdissected cells from pancreatic ductal adenocarcinoma precursor lesions,"Methods inMolecular Biology, vol. 425, pp. 1-14, 2008.
39. S. Viswanathan, M. Ünlü, and J. S. Minden, "Two-dimensional difference gel electrophoresis," Nature Protocols, vol. 1, no. 3, pp.1351-1358, 2006.
40. B. Sitek, J. Lüttges, K. Marcus et al., "Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma," Proteomics, vol. 5, no. 10, pp. 2665-2679, 2005.
41. R. Huttenhain, J. Malmström, P. Picotti, and R. Aebersold, "Perspectives of targeted mass spectrometry for protein biomarker verification," Current Opinion in Chemical Biology, vol. 13, no.5-6, pp. 518-525, 2009.
42. A. J. Percy, A. G. Chambers, J. Yang, and C. H. Borchers, "Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma," Proteomics, vol. 13, no. 14, pp. 2202-2215, 2013.
43. D. Domanski, A. J. Percy, J. Yang et al., "MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma," Proteomics, vol. 12, no. 8, pp.1222-1243, 2012.
44. P. Picotti and R. Aebersold, "Selected reaction monitoringbased proteomics: workflows, potential, pitfalls and future directions," Nature Methods, vol. 9, no. 6, pp. 555-566, 2012.
45. V. Gumpp and H. Henß, Klinisches Krebsregister Kodierhilfe- Prostata (1), Comprehensive Cancer Center, Freiburg, Germany, 2010.
46. A. Mortezavi, T. Hermanns, H.-H. Seifert et al., "KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy," Clinical Cancer Research, vol. 17, no. 5, pp. 1111-1121, 2011.
47. O.-P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter, "Tissue microarray technology for high-throughputmolecular profiling of cancer," HumanMolecular Genetics, vol. 10, no. 7, pp.657-662, 2001.
48. K. Labbus, M. Henning, E. Borkham-Kamphorst et al., "Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions," Journal of Proteomics, vol. 78, pp.188-196, 2013.
49. M. Berth, F. M. Moser, M. Kolbe, and J. Bernhardt, "The state of the art in the analysis of two-dimensional gel electrophoresis images," Applied Microbiology and Biotechnology, vol. 76, no. 6, pp. 1223-1243, 2007.
50. G. Corona, E. de Lorenzo, C. Elia et al., "Differential proteomic analysis of hepatocellular carcinoma," International Journal of Oncology, vol. 36, no. 1, pp. 93-99, 2010.
51. M. Hosako, T. Muto, Y. Nakamura et al., "Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker," Journal of Proteomics, vol. 75, no. 3, pp. 833-844, 2012.
52. F. Oshita, A. Morita, H. Ito et al., "Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer," Oncology Reports, vol.24, no. 3, pp. 637-645, 2010.
53. D. A. Megger, T. Bracht, M. Kohl et al., "Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and labelfree quantitative proteomics study," Molecular and Cellular Proteomics, vol. 12, no. 7, pp. 2006-2020, 2013.
54. W. Remmele and H. E. Stegner, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue," Pathologe, vol. 8, no. 3, pp. 138-140, 1987.
55. N. Selevsek, M. Matondo, M. S. Carbayo, R. Aebersold, and B. Domon, "Systematic quantification of peptides/proteins in urine using selected reaction monitoring," Proteomics, vol. 11, no. 6, pp. 1135-1147, 2011.
56. M. A. Kuzyk, D. Smith, J. Yang et al., "Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma," Molecular and Cellular Proteomics, vol. 8, no. 8, pp. 1860-1877, 2009.
57. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
58. L. C. Fang, M. Dattoli, A. Taira, L. True, R. Sorace, and K. Wallner, "Prostatic acid phosphatase adversely affects causespecific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy," Urology, vol. 71, no.1, pp. 146-150, 2008.
59. A. Taira, G. Merrick, K. Wallner, and M. Dattoli, "Reviving the acid phosphatase test for prostate cancer," Oncology, vol. 21, no.8, pp. 1003-1010, 2007.
60. H. Y. Kong and J. Byun, "Emerging roles of human prostatic acid phosphatase," Biomolecules and Therapeutics, vol. 21, no. 1, pp.10-20, 2013.
61. J. Ellerhorst, P. Troncoso, X.-C. Xu, J. Lee, and R. Lotan, "Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer," Urological Research, vol. 27, no. 5, pp. 362-367, 1999.
62. F. A. Van Den Brûle, D. Waltregny, F.-T. Liu, and V. Castronovo, "Alteration of the cytoplasmic/nuclear expression pattern of Galectin-3 correlates with prostate carcinoma progression," International Journal of Cancer, vol. 89, no. 4, pp. 361-367, 2000.
63. A. S. Merseburger, M. W. Kramer, J. Hennenlotter et al., "Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer," Prostate, vol. 68, no.1, pp. 72-77, 2008.
64. A. B. Gutman and E. B. Gutman, "An "acid" phophatase occuring in the serum of patients with metastasizing carcinoma of the prostate gland," The Journal of Clinical Investigation, vol.17, no. 4, pp. 473-478, 1938.
65. T. Bhavsar, P. McCue, and R. Birbe, "Molecular diagnosis of prostate cancer: are we up to age?" Seminars in Oncology, vol.40, no. 3, pp. 259-275, 2013.
66. J. F. Bogdanowicz, F. M. Bentvelsen, R. Oosterom, and F.H. Schroeder, "Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia," Scandinavian Journal of Urology and Nephrology, Supplement, vol. 138, pp. 97-103, 1991.
67. H. Ahmed, F. Cappello, V. Rodolico, and G. R. Vasta, "Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer," Translational Oncology, vol. 2, no. 3, pp. 146-156, 2009.
68. S. Califice, V. Castronovo, M. Bracke, and F. van den Břule, "Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3," Oncogene, vol. 23, no. 45, pp. 7527-7536, 2004.
69. M. R. De Melo-Júnior, J. L. S. Araújo-Filho, C. A. B. Lins, N.T. De Pontes-Filho, and L. B. De Carvalho Jr., "Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis," Applied Biochemistry and Biotechnology, vol. 160, no. 8, pp. 2198-2207, 2010.
70. H. Ahmed, "Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples," Biomarkers in Cancer, vol. 2010, no.2, pp. 17-33, 2010.
71. J. Fan, D. Yan, M. Teng et al., "Digital transcript profile analysis with aRNA-LongSAGE validates FERMT1 as a potential novel prognostic marker for colon cancer," Clinical Cancer Research, vol. 17, no. 9, pp. 2908-2918, 2011.
72. N. Miyoshi, H. Ishii, K. Mimori, M. Sekimoto, Y. Doki, and M. Mori, "SCRN1 is a novel marker for prognosis in colorectal cancer," Journal of Surgical Oncology, vol. 101, no. 2, pp. 156-159, 2010.
73. T. Suda, T. Tsunoda, N. Uchida et al., "Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNAmicroarray," Cancer Science, vol. 97, no. 5, pp. 411-419, 2006.
74. E. Sabo, P. A. Meitner, R. Tavares et al., "Expression analysis of barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue," Clinical Cancer Research, vol. 14, no. 20, pp. 6440-6448, 2008.
75. Y. Suehara, N. Tochigi, D. Kubota et al., "Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics," Journal of Proteomics, vol. 74, no. 6, pp. 829-842, 2011.
76. C. Ruiz, D. R. Holz, M. Oeggerli et al., "Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer," Journal of Pathology, vol. 223, no. 4, pp. 543-552, 2011.
77. K. Thorsen, K. D. Sørensen, A. Brems-Eskildsen et al., "Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis,"Molecular & Cellular Proteomics, vol. 7, no.7, pp. 1214-1224, 2008.
78. S.-L. Liang and D. W. Chan, "Enzymes and related proteins as cancer biomarkers: a proteomic approach," Clinica Chimica Acta, vol. 381, no. 1, pp. 93-97, 2007.
79. T. Kondo, "Tissue proteomics for cancer biomarker development- laser microdissection and 2D-DIGE," Journal of Biochemistry and Molecular Biology, vol. 41, no. 9, pp. 626-634, 2008.
80. G. Chen, T. G. Gharib, C.-C. Huang et al., "Discordant protein and mRNA expression in lung adenocarcinomas," Molecular & Cellular Proteomics, vol. 1, no. 4, pp. 304-313, 2002.
81. D. K. Ornstein and E. F. Petricoin III, "Proteomics to diagnose human tumors and provide prognostic information," Oncology, vol. 18, no. 4, pp. 521-532, 2004.
82. K. S. Lilley, A. Razzaq, and P. Dupree, "Two-dimensional gel electrophoresis: Recent advances in sample preparation, detection and quantitation," Current Opinion in Chemical Biology, vol. 6, no. 1, pp. 46-50, 2002.
83. S. A. Dyshlovoy, I. Naeth, S. Venz et al., "Proteomic profiling of germcell cancer cells treated with aaptamine, amarine alkaloid with antiproliferative activity," Journal of Proteome Research, vol.11, no. 4, pp. 2316-2330, 2012.
84. N. Chignard and L. Beretta, "Proteomics for hepatocellular carcinomamarker discovery," Gastroenterology, vol. 127, supplement 1, no. 5, pp. S120-S125, 2004.
85. N. A. Karp, R. Feret, D. V. Rubtsov, and K. S. Lilley, "Comparison of DIGE and post-stained gel electrophoresis with both traditional and SameSpots analysis for quantitative proteomics," Proteomics, vol. 8, no. 5, pp. 948-960, 2008.
86. J. F. Timms and R. Cramer, "Difference gel electrophoresis," Proteomics, vol. 8, no. 23-24, pp. 4886-4897, 2008.